[
  {
    "date": "2023-12-30",
    "symbol": "MDXH",
    "period": "FY",
    "revenuefromrenderingofservices": 69965000,
    "royaltiesandotherrevenues": 228000,
    "revenue": 70193000,
    "costofsales": 26264000,
    "grossprofit": 43929000,
    "researchanddevelopmentexpense": 6376000,
    "salesandmarketingexpense": 36915000,
    "generalandadministrativeexpense": 23010000,
    "impairmentlossonfinancialassets": 4494000,
    "otheroperatingincomeexpense": -461000,
    "profitlossfromoperatingactivities": -27327000,
    "financeincome": 2570000,
    "financecosts": 18342000,
    "profitlossbeforetax": -43099000,
    "incometaxexpensecontinuingoperations": 1000,
    "profitloss": -43100000,
    "basicearningslosspershare": -1.66,
    "dilutedearningslosspershare": 1.66,
    "gainslossesonexchangedifferencesontranslationnetoftax": -149000,
    "othercomprehensiveincome": -149000,
    "comprehensiveincome": -43249000,
    "goodwill": 35926000,
    "intangibleassetsotherthangoodwill": 44337000,
    "propertyplantandequipment": 4956000,
    "rightofuseassets": 4989000,
    "financialassets": 763000,
    "noncurrentassets": 90971000,
    "inventories": 2779000,
    "tradeandothercurrentreceivables": 11088000,
    "currentprepaidexpenses": 1914000,
    "cashandcashequivalents": 22380000,
    "currentassets": 38161000,
    "assets": 129132000,
    "issuedcapital": 173931000,
    "issuancepremium": 153177000,
    "retainedearnings": -331446000,
    "reserveofsharebasedpayments": 12139000,
    "reserveofexchangedifferencesontranslation": -593000,
    "equity": 7208000,
    "borrowings": 35564000,
    "noncurrentleaseliabilities": 3578000,
    "othernoncurrentfinancialliabilities": 63259000,
    "noncurrentliabilities": 102401000,
    "currentportionoflongtermborrowings": 643000,
    "currentleaseliabilities": 1480000,
    "tradeandothercurrentpayablestotradesuppliers": 8811000,
    "othercurrentliabilities": 5694000,
    "othercurrentfinancialliabilities": 2895000,
    "currentliabilities": 19523000,
    "liabilities": 121924000,
    "equityandliabilities": 129132000,
    "numberofsharesoutstanding": 27288093,
    "issueofequity": 39599000,
    "increasedecreaseinnumberofordinarysharesissued": 10750000,
    "increasedecreasethroughtransfersandotherchangesequity": 878000,
    "increasedecreasethroughtransfersandotherchangeequity": 250000,
    "adjustmentsforsharebasedpayments": 665000,
    "cashflowsfromusedinoperations": -27327000,
    "adjustmentsfordepreciationandamortisationexpense": 2365000,
    "adjustmentsforamortisationexpense": 4494000,
    "othernoncashtransactions": 421000,
    "cashflowsfromusedinoperationsbeforechangesinworkingcapital": -19382000,
    "adjustmentsfordecreaseincreaseininventories": -452000,
    "adjustmentsfordecreaseincreaseintradeaccountreceivable": -1683000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 20000,
    "cashflowsfromusedinoperatingactivities": -21497000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 2747000,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 2272000,
    "interestreceivedclassifiedasinvestingactivities": 1088000,
    "cashflowsfromusedininvestingactivities": -3931000,
    "proceedsfromissuingshares": 39599000,
    "paymentoflongtermdebt": 1659000,
    "repaymentsofborrowingsclassifiedasfinancingactivities": 250000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 1610000,
    "paymentofinterest": 3610000,
    "paymentsofotherequityinstruments": 190000,
    "cashflowsfromusedinfinancingactivities": 32280000,
    "netdecreaseincashandcashequivalents": 6852000,
    "cashandcashequivalentsifdifferentfromstatementoffinancialposition": 22380000,
    "effectofexchangeratechangesoncashandcashequivalents": 25000,
    "descriptionofaccountingpolicyforbasisofpreparationandstatementofcompliancetextblock": "2.1.Basis of preparation and statement of compliance",
    "descriptionofaccountingpolicyforconsolidationtextblock": "2.2.Basis of consolidation",
    "descriptionofaccountingpolicyforgoingconcerntextblock": "2.3.Going Concern",
    "useofestimatespolicytextblock": "2.4.Use of estimates and judgments",
    "newstandardsinterpretationsandamendmentspolicytextblock": "2.5.New Standards, Interpretations and Amendments",
    "segmentinformationpolicytextblock": "2.8.Segment information",
    "rightofuseassetsandliabilitiespolicytextblock": "2.11.Right-of-use assets and liabilities",
    "descriptionofaccountingpolicyfortaxationtextblock": "2.15.Taxation",
    "descriptionofaccountingpolicyforsharecapitalpolicytextblock": "2.16.Share Capital",
    "descriptionofaccountingpolicyforfinancialassets": "2.17.Financial Assets",
    "descriptionofaccountingpolicyforfinancialliabilitiestextblock": "2.18.Financial Liabilities",
    "descriptionofaccountingpolicyforretirementbenefitschemesandemployeesavingsschemestextblock": "2.19.Retirement benefit plans and employee savings plans",
    "descriptionofaccountingpolicyforsharesbasedcompensationplansforpersonneldirectorsandbusinessassociatestextblock": "2.20.Share-based compensation plans for personnel, directors and business associates",
    "disclosureofacquisitionconsiderationtable": "The acquisitionconsideration was comprised of (in thousands of $):",
    "disclosureoffairvalueoftheidentifiableassetstable": "Thefair value of the identifiable assets at the date of acquisition were:",
    "disclosureofrevenuetabletextblock": "Thousands of $ For the years ended December 31      2023       2022       2021       Services      69,965       36,965       21,937       Royalties and other revenues      228       89       302       Total revenue      70,193       37,054       22,239",
    "disclosureofrevenuefromexternalcustomersbrokendownbylocationtabletextblock": "Theamount of its revenue from external customers broken down by location is shown in the table below:",
    "disclosureofcostofsalestabletextblock": "Thousands of $ For the years ended December 31      2023      2022       2021       Cost of sales      26,264       17,835       11,675       Total cost sales      26,264       17,835       11,675",
    "scheduleofresearchanddevelopmentexpensestabletextblock": "Researchand development expenses",
    "scheduleofsellingandmarketingexpensestabletextblock": "Sellingand Marketing expenses",
    "scheduleofgeneralandadministrativeexpensestabletextblock": "Generaland administrative expenses",
    "scheduleofamortizationofintangibleassetstabletextblock": "Amortizationof intangible assets",
    "scheduleofotheroperatingincomeexpensesnettextblock": "Thousands of $ For the years ended December 31      2023       2022       2021       Grant subsidies – The Netherlands      62       5       382       Grant subsidies – USA      -       -       659       Fair value adjustments      (588)      515       176       Other operating income      65       39       53       Other operating expenses      -       -       (109)      Total other operating (expense) income, net      (461)      559       1,161",
    "scheduleoffinanceincomeexpensestabletextblock": "FinancialIncome",
    "scheduleoftaxreconciliationandimpactofunrecognizeddeferredtaxassetstabletextblock": "The tax reconciliation and the impact of the unrecognizeddeferred tax assets is as follows:",
    "scheduleofleaserecognizedtabletextblock": "Thefollowing amounts related to leases are recognized in the statement of profit or loss:",
    "inventoriestabletextblock": "Thousands of $ For the years ended December 31     2023      2022       Raw materials and consumables      2,779       2,327       Total Inventories     $2,779      $2,327",
    "scheduleoftradereceivablestabletextblock": "Thousands of $ For the years ended December 31      2023       2022       Trade receivables      11,088       9,357       Total trade receivables      11,088       9,357",
    "scheduleoftotalaccountsreceivablebalancewiththeclaimdatetabletextblock": "Consideringthe Company’s revenue recognition methodology further described in Note 2.7, total accounts receivable balance could be presentedin relation with the claim date of each sample as follows:",
    "scheduleofprepaidexpensesandothercurrentassetstabletextblock": "Thousandsof $ For the years ended December 31      2023       2022       Prepayments      1,585       1,710       Deposits      110       101       Recoverable VAT      183       97       Grants to be received      -       54       Other      36       -       Total prepaid expenses and other current assets     $1,914      $1,962",
    "scheduleofcashandcashequivalenttabletextblock": "Thousands of $ For the years ended December 31      2023       2022       Cash and cash equivalents      22,380       15,503       Total cash and cash equivalents     $22,380      $15,503",
    "disclosureofloansborrowingsleaseliabilitiestabletextblock": "Loans,Borrowings & Lease liabilities",
    "disclosureofmaturityofloansandborrowingstabletextblock": "Maturityof loans and borrowings are as follows at the balance sheet date:",
    "disclosureofotherfinancialliabilitiestabletextblock": "Thousands of $ For the years ended December 31      2023       2022       Other financial liabilities                    Other non-current financial liabilities      63,259       53,537       Other current financial liabilities      2,895       2,327       Total other financial liabilities      66,154       55,864",
    "disclosureofcashandnoncashmovementsofloansandborrowingstabletextblock": "Areconciliation of cash and non-cash movements of loans and borrowings, lease liabilities and other financial liabilities is presentedbelow:",
    "disclosureoffairvalueadjustmentsrecognizedtabletextblock": "Fairvalue adjustments recognized during 2023 for other financial liabilities relate to:",
    "disclosureofleaseliabilitiestabletextblock": "Thousands of $     Lease liabilities       For the years ended December 31     2023      2022       Opening balance      4,263       3,464       Cash movements                      Repayment of lease liabilities      (1,610)      (1,358)      Non-cash movements                      Interest accretion      355       314       New leases      2,050       1,843       Closing balance      5,058       4,263",
    "scheduleofcontractualobligationstabletextblock": "Thousands of $ For The Years ended December 31      2023       2022       Outstanding commitments for future minimum rent payments, which fall due as follows:                    Less than one year      90       156       Years 2-5      53       60       Total contractual obligations      143       216",
    "scheduleoftradeaccountspayabletabletextblock": "Thousands of $ For The Years ended December 31      2023       2022       Trade accounts payable      4,889       5,061       Accruals for invoices to be received      3,922       5,117       Total trade accounts payable      8,811       10,178",
    "scheduleofothercurrentliabilitiestabletextblock": "Thousands of $ For The Years ended December 31      2023       2022       Payroll      5,222       3,932       Other accruals      472       53       Total other current liabilities      5,694       3,985",
    "disclosureofassetsandliabilitiesareconsideredtohavecarryingamountstabletextblock": "Allfinancial assets and liabilities are considered to have carrying amounts that do not materially differ from their fair value.",
    "disclosureofreconciliationofcashandnoncashmovementstabletextblock": "Areconciliation of cash and non-cash movements of level 3 financial liabilities is presented below:",
    "scheduleofsharecapitalnumberofsharestabletextblock": "AtDecember 31, 2023 and 2022, the Company’s share capital was represented by the following number of shares, adjusted for the 1-for-10reverse stock split that took place in November 2023. Only one class of shares (common shares) exists and they have no par value.",
    "scheduleofcapitalstockandtheissuancepremiumtabletextblock": "The capitalstock and the issuance premium amounted to the following:",
    "disclosureofoutstandingwarrantstabletextblock": "Outstanding warrants     2023      2022       Warrants created      2,060,000       1,731,080       Warrants available for grant      (208,250)      (163,750)      Warrants granted      1,851,750       1,567,330       Warrants terminated or lapsed      (213,977)      (283,840)      Warrants exercised      -       (57,712)      Total outstanding at December 31      1,637,773       1,225,778",
    "disclosureofpotentialsharesfromoutstandingwarrantstabletextblock": "Number of potential shares from outstanding warrants     2023      2022       As of January 1      1,225,778       891,763       Number of warrants cancelled/forfeited during the year      (43,505)      (59,035)      Number of warrants granted during the year      455,500       393,050       As of December 31      1,637,773       1,225,778",
    "disclosureofsharebasedcompensationexpenserecognizedinthestatementofcomprehensiveincomeexplanatory": "Theshare-based compensation expense recognized in the consolidated statement of profit or loss is given below as is the cumulated amountper the consolidated statement of financial position:",
    "disclosureoftheoutstandingpotentialsharesfromwarrantsperpersonnelcategorytabletextblock": "Thefollowing table provides an overview of the outstanding potential shares from warrants per personnel category at December 31, 2023 and2022:",
    "disclosureoffairvalueofeachwarrantisestimatedonthedateofgrantusingtheblackscholesmethodologytabletextblock": "Thefair value of each warrant is estimated on the date of grant using the Black-Scholes methodology with the following assumptions:",
    "scheduleofcombinedremunerationpackageincludingemployertaxestabletextblock": "Their combinedremuneration package, including employer taxes, amounted to the following:",
    "disclosureofwarrantstabletextblock": "Thefollowing table sets forth the number of warrants that were exercised, granted and accepted in aggregate by the four members of the executivemanagement team:",
    "scheduleofwhollyowneddirectsubsidiariestabletextblock": "The Companyhas the following two wholly-owned direct subsidiaries:",
    "scheduleofstatutoryauditorperformedadditionalactivitiestabletextblock": "Thedetail is presented in the table below:",
    "cashtransferred": 25000000,
    "stocktransferred": 5000000,
    "contingentconsiderationsrecognisedasofacquisitiondate": 50483000,
    "acquisitiondatefairvalueoftotalconsiderationtransferred": 80483000,
    "intangibleassetsacquiredbywayofgovernmentgrantatfairvalue": 36550000,
    "intangibleassetsipbrandfairvalueatacquisitiondate": 36550000,
    "intangibleassetscustomerrelationshipsfairvalueadjustments": 8007000,
    "intangibleassetscustomerrelationshipsfairvalueatacquisitiondate": 8007000,
    "identifiedassetsfairvalueadjustments": 44557000,
    "identifiedassetsfairvalueatacquisitiondate": 44557000,
    "goodwillfairvalueadjustments": 35926000,
    "goodwillfairvalueatacquisitiondate": 35926000,
    "acquisitionpricefairvalueatacquisitiondate": 80483000,
    "revenuefromsaleofgold": 69965000,
    "totalsegmentrevenue": 69708000,
    "totalcostsales": 26264000,
    "keymanagementpersonnelcompensation": 3693000,
    "depreciationandamortisationexpenses": 428000,
    "labconsumables": 639000,
    "patentexpenses": 83000,
    "externalresearchanddevelopmentcollaboratorfees": 199000,
    "clinicalvalidation": 765000,
    "otherexpensebynature": 569000,
    "keymanagementpersonnelcompensations": 27952000,
    "depreciationexpense": 888000,
    "professionalfeesexpense": 710000,
    "marketingexpenses": 5075000,
    "travelexpenses": 1061000,
    "officesfacilitiesexpenses": 459000,
    "otherexpensebyfunction": 770000,
    "totalsellingandmarketingexpenses": 36915000,
    "personnelcost": 10184000,
    "depreciationandamortisationexpense": 737000,
    "professionalfeesexpenses": 6706000,
    "publiccompanyexpenses": 2701000,
    "travelexpense": 130000,
    "officesfacilitiesexpense": 1266000,
    "revenuefromroyalties": 28000,
    "boardfees": 366000,
    "otherexpense": 892000,
    "totalamortizationofintangibleassets": 4494000,
    "operatingexpense": 79000,
    "laboratorystaffheadcount": 31000,
    "smstaffheadcount": 106000,
    "gastaffheadcount": 84000,
    "totalnumberofemployees": 300000,
    "wagesandsalaries": 31388000,
    "socialsecuritycosts": 2682000,
    "otherlongtermbenefits": 1153000,
    "insuranceexpense": 5058000,
    "othercosts": 883000,
    "totalpersonnelcosts": 41829000,
    "interestincomeondebtinstrumentsheld": 1088000,
    "currentderivativefinancialliabilities": 719000,
    "fairvalueofoptiontopaygpsearnoutinsharesinshares": 763000,
    "financeincomecost": 2570000,
    "interestexpenseondebtinstrumentsissued": 5232000,
    "interestexpenseonbankloansandoverdrafts": 350000,
    "adjustmentsforgainslossesonchangeinfairvalueofderivatives": -9105000,
    "otherfinancialloss": -190000,
    "gpsamendmentadditionalconsiderationpaymentincash": -250000,
    "gpsamendmentadditionalconsiderationpaymentinshares": -878000,
    "netfinancialresults": -18342000,
    "warrantsterm": "P5Y",
    "lossfortheyear": 43100000,
    "deferredtaxexpenseincomerelatingtooriginationandreversaloftemporarydifferences": -1000,
    "lossbeforeincometax": 43099000,
    "taxusingthemdxhealthsdomestictaxrate": 10775000,
    "deferredtaxassets": 10775000,
    "goodwillamount": 35900000,
    "carryingvalue": 35926000,
    "descriptionofdiscountratesusedincurrentestimateofvalueinuse": 0.1283,
    "terminalgrowthrate": 0.02,
    "additionsotherthanthroughbusinesscombinationpropertyplantandequipment": -2660000,
    "currencytranslationadjustmentsgrossvalue": 5000,
    "grossvalueendingbalance": 5134000,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 343000,
    "accumulatedamortizationandimpairmentendingbalances": -5134000,
    "netvalue": 3972000,
    "propertyplantandequipmentsgrossvalue": 8816000,
    "propertyplantandequipmentaccumulateddepreciation": -6178000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 2638000,
    "propertyplantandequipmentgrossadditions": 1312000,
    "propertyplantandequipmentgrossdisposals": -111000,
    "transferfromleasesgrossvalue": 498000,
    "exchangeratedifferencearisinggross": -62000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 558000,
    "disposalspropertyplantandequipment": 108000,
    "transferfromleasesaccumulateddepreciation": -498000,
    "exchangeratedifferencearising": 62000,
    "rightofuseassetsgrossvalue": 7291000,
    "rightofuseassetsgrossadditions": 726000,
    "grossvaluedisposals": -114000,
    "grossvaluetransfertotangibleassets": -498000,
    "rightofuseassetsaccumulatedamortizationbeginning": -3946000,
    "rightofuseassetsadditions": -1079000,
    "accumulateddepreciationdisposals": 70000,
    "accumulateddepreciationtransfertotangibleassets": 498000,
    "accumulateddepreciationexchangeratedifference": 7000,
    "rightofuseassetnetvalue": 3345000,
    "propertyplantequipmentdepreciationexpense": 1187000,
    "interestexpenseonleaseliabilities": 284000,
    "noncurrentinventories": 2779000,
    "tradereceivables": 11088000,
    "tradeandotherreceivables": 11088000,
    "currentprepayments": 1585000,
    "shorttermdepositsnotclassifiedascashequivalents": 110000,
    "recoverablevat": 183000,
    "otherpayables": 36000,
    "othercurrentassets": 1914000,
    "othercashandcashequivalents": 22380000,
    "loanspayablesnoncurrent": 35564000,
    "interestexpenseonleaseliability": 3578000,
    "totalnoncurrentloansandborrowings": 39142000,
    "loanspayablescurrent": 643000,
    "totalcurrentloansandborrowings": 2123000,
    "loanswithinoneyear": 643000,
    "loansyearstwotofive": 35564000,
    "leaseswithinoneyear": 1900000,
    "leasesyearstwotofive": 3955000,
    "financialliabilitiesatamortisedcost": 63259000,
    "otherfinancialliabilities": 66154000,
    "otherprovisions": 36207000,
    "loansandborrowingsrepaid": -637000,
    "interestrevenuecalculatedusingeffectiveinterestmethod": 1314000,
    "foreignexchangerateimpactother": -4000,
    "gainslossesonfinancialassetsatfairvaluethroughprofitorlossclassifiedasheldfortrading": 11316000,
    "increaseofnoviogendixcontingentconsideration": 16000,
    "increaseofkreosderivativefinancialinstrumentinitialdrawdownfee": 135000,
    "increaseofgpscontingentconsideration": 9730000,
    "decreaseofinnovatusembeddedderivativeconvertiblecalloption": -718000,
    "exactsciences5yearwarrants": 2153000,
    "totalfairvalueadjustment": 11316000,
    "exactscienceswarrants": "P5Y",
    "leaseliabilities": 5058000,
    "repaymentofleaseliabilities": 1610000,
    "interestexpense": 355000,
    "cashoutflowforleases": 2050000,
    "ontractualobligationlessthanoneyear": 90000,
    "contractualobligationssecondtofifthyear": 53000,
    "contractualobligations": 143000,
    "tradeandotherpayablestotradesuppliers": 4889000,
    "accrualsforinvoicestobereceived": 3922000,
    "tradeandothercurrentpayables": 8811000,
    "payroll": 5222000,
    "otheraccruals": 472000,
    "totalothercurrentliabilities": 5694000,
    "totalfinancialassetsatamortizedcost": 33468000,
    "gpscontingentconsideration": 62611000,
    "exactsciences5yearwarrantsatfairvalue": 2153000,
    "noviogendixcontingentconsideration": 1198000,
    "innovatusderivativeinstrument": 192000,
    "financialliabilitiesatfairvalue": 2200000,
    "loansandborrowingss": 36207000,
    "leaseliabilitiesoffinancialinstruments": 5058000,
    "tradeandotherpayables": 8811000,
    "subtotalfinancialliabilitiesatamortizedcost": 50076000,
    "financialliabilities": 116230000,
    "exactscienceswarrantsatfairvalue": "P5Y",
    "cashequivalents": 192000,
    "deferredacquisitioncostsarisingfrominsurancecontracts": 65962000,
    "loansreceived": 1022000,
    "contingentconsiderationloansandborrowingsrepaid": -250000,
    "contingentconsiderationexactsciences5yearwarrant": 2153000,
    "currentinterestpayable": 4000,
    "fairvaluechangesthroughprofitandloss": 9996000,
    "transfersoutoflevel2intolevel1offairvaluehierarchyliabilities": 136000,
    "financialderivativeinstrumentexactscienceswarrant": "P5Y",
    "contingentconsiderationexactscienceswarrant": "P5Y",
    "profitlossattributabletoownersofparent": -43100000,
    "basicearningslosspersharefromdiscontinuedoperations": -1.66,
    "weightedaverageshares": 25910696,
    "dilutedearningslosspersharefromdiscontinuedoperations": -1.66,
    "adjustedweightedaverageshares": 25910696,
    "tradeandotherpayablesundiscountedcashflows": 8811000,
    "loansandadvancestocustomers": 650000,
    "grossleaseliabilities": 1900000,
    "nonderivativeundiscountedcashflowstotal": 11361000,
    "numberofsharesauthorised": 27288093,
    "sharecapitalsituationatending": 173931000,
    "issuancepremiumsituationatending": 153177000,
    "sharecapitalissuancesharesone": 39599000,
    "sharecapitalasperstatutoryaccounts": 192297000,
    "capitalincreasecosts": -18366000,
    "sharecapitalunderifrs": 173931000,
    "issuancepremiums": 153177000,
    "sharecapitalandissuancepremium": 327108000,
    "warrantscreated": 2060000,
    "warrantsavailableforgrantinshares": -208250,
    "warrantsgranted": 1851750,
    "warrantsterminatedorlapsedindollarspershares": -213977,
    "warrantsoutstanding": 1637773,
    "numbersofshareoutstanding": 1637773,
    "numberofwarrantcancelledforfeitedduringtheyear": -43505,
    "numberofwarrantgrantedduringtheyear": 455500,
    "sharebasedcompensation": 665000,
    "cumulatedsharebasedcompensation": 12139000,
    "outstandingwarrantsbeginning": 455500,
    "weightedaverageexercisepricegranted": 2.91,
    "outstandingpotentialsharesfromexerciseofwarrantsbeginning": 455500,
    "weightedaverageexercisepriceperpotentialsharegranted": 2.91,
    "outstandingwarrantsending": 1637773,
    "outstandingweightedaverageexercisepriceending": 9.64,
    "outstandingpotentialsharesfromexerciseofwarrantsending": 1637773,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 9.64,
    "sharwbasedpaymentoutstandingwarrantsexercisableshares": 759841,
    "weightedaverageexercisepriceoutstandingexercisable": 14.07,
    "outstandingpotentialsharesfromexerciseofwarrantsexercisable": 759841,
    "weightedaverageexercisepriceperpotentialshareoutstandingexercisable": 14.07,
    "executivedirectorinshares": 489375,
    "nonexecutivedirectors": 25650,
    "managementteamexcludingtheexecutivedirector": 517912,
    "otheremployeesconsultantsandformerserviceproviders": 604836,
    "totaloutstanding": 1637773,
    "numberofwarrantsgrantedtobelgianfenef": 1200,
    "numberofwarrantsgrantedtootherbenef": 1200,
    "exerciseprice": 41.3,
    "expectedstockpricevolatilities": 0.4812,
    "riskfreeinterestrates": 0.0178,
    "riskfreeinterestrate": 0.7532,
    "expecteddurationmonthstobelgianbenef": "P63M8D",
    "numberofmanagementmembersandexecutivedirectors": 4,
    "shorttermemployeebenefitsexpense": 1967000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 48000,
    "otherfinancecost": 216000,
    "increasedecreaseinnetdefinedbenefitliabilityasset": 2231000,
    "ifrssharebasedcompensationexpense": 909000,
    "numberofwarrantsofferedinshares": 220000,
    "cumulativeoutstandingwarrants": 1007287,
    "exercisablewarrants": 644283,
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 220000000,
    "financialassetsatfairvalue": 909000000,
    "addressofregisteredofficeofentity": "15279 Alton Parkway – Suite 100 – Irvine, CA 92618",
    "incorporationdate": "2003-04-14",
    "countryofincorporationdate": "2015-09-18",
    "auditfeeforstatutoryandconsolidatedfinancial": 408000,
    "auditrelatedandotherservicesipointheusa": 40000,
    "statutoryauditorperformancetotal": 448000,
    "collegeofamericanpathologists": 13448,
    "accumulatedothercomprehensiveincome": 331400000,
    "netloss": 43100000,
    "netcashusedinoperatingactivities": 21500000,
    "cashequivalent": 22400000,
    "outstandingownershippercentage": 0.075,
    "estimatedfinancialeffectofcontingentassets": 800000,
    "rightofwarrantacquireshares": 1000000,
    "warrantpricepershares": 5.265,
    "estimatedfinancialeffectofcontingentliabilities": 2200000,
    "subscriptionrightofwarrantduringaperiod": "P5Y",
    "aggregatenumberofsharesexceeds": 0.075,
    "adjustmentsforgainslossesonfairvalueadjustmentinvestmentproperty": 9100000,
    "purchaseagreementamendment": 600000,
    "actuarialassumptionofdiscountrates": 0.1283,
    "borrowingsinterestrate": 0.1283,
    "estimatedamount": 1200000,
    "amountconsideredincurrent": 550000,
    "estimatedvalue": 192000,
    "impairmentterm": "P5Y",
    "perpetualgrowthrate": 0.02,
    "interestrate": "P10Y",
    "amountofexchangerateappliedforassetsandliabilities": 1,
    "amountofexchangerateappliedforincomeandexpenses": 1,
    "intellectualproperty": "P10Y",
    "customers": "P6Y6M",
    "capitalizeddevelopmentcosts": "P5Y",
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P5Y",
    "depreciationperiodsrange": "P3Y",
    "percentageofbuildings": 0.1,
    "percentageofvehicles": 0.025,
    "percentageofmaterials": 0.0975,
    "tradereceivable": "P1Y",
    "outstandingaggregateprincipalamount": 0.15,
    "aggregatepurchaseprice": 100000000,
    "settledliabilitiescontingentliabilitiesrecognisedinbusinesscombination": 5000000,
    "americandepositarysharesissued": 691171,
    "parvaluepershare": 7.23,
    "aggregateearnoutamount": 70000000,
    "sharesoutstandingpercentage": 0.05,
    "disposalsintangibleassetsandgoodwill": 35900000,
    "acquisitiondatefairvalueofequityinterestinacquireeheldbyacquirerimmediatelybeforeacquisitiondate": 44600000,
    "royaltypercentage": 0.0956,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P15Y",
    "discountrateusedinvaluation": 0.1495,
    "contingentconsiderationrecognisedasofacquisitiondate": 1200000,
    "otherrevenue": 30900000,
    "loansandreceivables": 35000000,
    "debtfacilityamount": 9000000,
    "sharesacquired": 1000000,
    "averagerateofhedginginstrument": 0.075,
    "percentageofentitysrevenue": 0.89,
    "customergeneratingover": 0.1,
    "totalrevenue": 27700000,
    "percentageofrevenuefromexternalcustomers": 0.997,
    "percentageofrevenue": 0.99,
    "percentageofintellectualpropertyrevenue": 0.01,
    "noncurrentasset": 0.91,
    "developmentpercentage": 0.16,
    "sellingexpense": 11200000,
    "percentageofmarketingexpenses": 0.44,
    "percentageofgeneralandadministrative": 0.01,
    "contingentconsiderationamount": 9100000,
    "interestchargesandextinguishmentexpenses": 5200000,
    "deferredtaxassetwhenutilisationisdependentonfuturetaxableprofitsinexcessofprofitsfromreversaloftaxabletemporarydifferencesandentityhassufferedlossinjurisdictiontowhichdeferredtaxassetrelates": 308700000,
    "taxcreditcarryforwardexpirationperiod": "P2021Y",
    "goodwillterm": "P5Y",
    "fairvalueofpropertyplantandequipmentmateriallydifferentfromcarryingamount": 88800000,
    "percentageofreasonablypossibleincreaseinunobservableinputassets": 0.01,
    "impairmentamount": 18900000,
    "growthratepercentage": 0.01,
    "decreaseinimpairmentamount": 13600000,
    "discountrate": 0.0728,
    "recoverableamountofassetorcashgeneratingunit": 8000000,
    "capitalizeddevelopmentexpenses": 2700000,
    "officeequipment": 1300000,
    "leaseholdsimprovements": 741000,
    "additionstorightofuseassets": 2300000,
    "costofinventoriesrecognisedasexpenseduringperiod": 5700000,
    "descriptionofloanaccrueinterest": "Theloans accrue interest at a floating per annum rate equal to the sum of (a) the greater of (i) the prime rate published in The Wall StreetJournal in the “Money Rates” section or (ii) 4.00%, plus (b) 4.25%, and require interest-only payments for the initial fouryears.",
    "percentageofoutstandingprincipalamount": 0.0225,
    "loanprice": 11.21,
    "totalloan": 0.01,
    "endofloanfee": 0.05,
    "fixedrate": 0.15,
    "debtfacilitypecentage": 0.7292,
    "convertibledebts": 180000,
    "outstandingamount": 1000000,
    "earnoutpayable": 30000000,
    "noncurrentderivativefinancialliabilities": 62600000,
    "financialassetsatfairvaluethroughprofitorloss": 800000,
    "fairvalueofwarrant": 1000000,
    "propertyplantandequipmentcarryingamountatcostofrevaluedassets": 5000,
    "variableinterestrate": 0.04,
    "interestratepercentage": 0.01,
    "weightedestimate": 82500000,
    "adjustmentsforfairvaluegainslosses": 10000000,
    "interestexpenseonotherfinancialliabilities": 9400000,
    "issuesfairvaluemeasurementassets": 192000,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.1,
    "acquireshares": 1000000,
    "shareprices": 3.94,
    "strikeprice": 5.265,
    "financialliabilitiesatfairvaluethroughprofitorloss": 2200000,
    "numberofcustomers": 1000,
    "noncurrentreceivables": 11100000,
    "creditriskcashequivalents": 22400000,
    "shorttermdepositsclassifiedascashequivalents": 357000,
    "exchangerate": 0.1,
    "loanagreements": 2,
    "numberofleases": 12,
    "percentageofoutstandingsshares": 0.075,
    "aggregateamount": 162640506.27,
    "issuanceofnewshares": 250000,
    "descriptionofsharesoutstanding": "●",
    "totalcost": 1200000,
    "debtsinstrumentterm": "P10Y",
    "warrantsunderstockoptionplansforgranttoconsultants": 2060000,
    "warrantoutstanding": 1637773,
    "sharessubscribe": 1637773,
    "warrantsterminatedorlapsed": 43505,
    "warrantsvested": 237789,
    "cumulativetranchespercentage": 0.25,
    "nonvestedprice": 9.64,
    "weightedaverageremainingcontractuallifeofoutstandingwarrants": "P7Y1M9D",
    "expectedvolatilityterm": "P2Y",
    "directorsremunerationexpense": 1090000,
    "expectedreimbursementotherprovisions": 29000,
    "reimbursementforexpenses": 337000,
    "currentheldtomaturityinvestments": 2200000,
    "fairvalueofacquiredreceivables": 1200000,
    "usefullifemeasuredasperiodoftimebiologicalassetsatcost": "P1Y",
    "entityregistrantname": "MDXHEALTH SA",
    "tradingsymbol": "MDXH",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "entitycommonstocksharesoutstanding": 27288093,
    "amendmentflag": "false",
    "entitycentralindexkey": 1872529,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "false",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-40996",
    "entityaddresscountry": "BE",
    "entityaddressaddressline1": "Zone Industrielle des Hauts-Sarts",
    "entityaddresspostalzipcode": 4040,
    "entityaddresscityortown": "Herstal",
    "entityincorporationstatecountrycode": "C9",
    "contactpersonnelname": "Michael McGarrity",
    "entityaddressaddressline2": "Suite 100",
    "cityareacode": "+1 949",
    "localphonenumber": "812-6979",
    "security12btitle": "Ordinary shares, no par value",
    "securityexchangename": "NASDAQ",
    "entityinteractivedatacurrent": "Yes",
    "documentfinstmterrorcorrectionflag": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorname": "BDO Réviseurs d’Entreprises SRL",
    "auditorlocation": "Zaventem, Belgium",
    "auditorfirmid": 1432
  },
  {
    "date": "2022-12-31",
    "symbol": "MDXH",
    "period": "FY",
    "services": 36965000,
    "licenses": 25000,
    "royaltiesandotherrevenues": 64000,
    "revenue": 9300000,
    "costofsales": 17835000,
    "grossprofit": 19219000,
    "researchanddevelopmentexpense": 7557000,
    "salesandmarketingexpense": 26582000,
    "generalandadministrativeexpense": 23539000,
    "otheroperatingincomeexpense": 602000,
    "profitlossfromoperatingactivities": -37900000,
    "financecosts": 6144000,
    "profitlossbeforetax": -44044000,
    "profitloss": -44044000,
    "basicearningslosspershare": -0.28,
    "dilutedearningslosspershare": 0.28,
    "gainslossesonexchangedifferencesontranslationnetoftax": 593000,
    "totalothercomprehensiveincomeloss": 593000,
    "comprehensiveincome": 593000,
    "goodwill": 35926000,
    "intangibleassetsotherthangoodwill": 46166000,
    "propertyplantandequipment": 3791000,
    "rightofuseassets": 4103000,
    "noncurrentassets": 89986000,
    "inventories": 2327000,
    "tradeandothercurrentreceivables": 9357000,
    "prepaidexpensesandothercurrentassets": 1962000,
    "cashandcashequivalents": 15503000,
    "currentassets": 29149000,
    "assets": 119135000,
    "issuedcapital": 133454000,
    "issuancepremium": 153177000,
    "retainedearnings": -288346000,
    "reserveofsharebasedpayments": 11474000,
    "translationreserve": -444000,
    "equity": -444000,
    "loansandborrowings": 34914000,
    "noncurrentleaseliabilities": 3091000,
    "othernoncurrentfinancialliabilities": 53537000,
    "noncurrentliabilities": 91542000,
    "currentportionoflongtermborrowings": 616000,
    "currentleaseliabilities": 1172000,
    "tradeandothercurrentpayablestotradesuppliers": 10178000,
    "othercurrentliabilities": 3985000,
    "othercurrentfinancialliabilities": 2327000,
    "currentliabilities": 18278000,
    "liabilities": 109820000,
    "equityandliabilities": 119135000,
    "numberofsharesoutstanding": 162880936,
    "othercomprehensiveincome": 593000,
    "issueofequity": 5000000,
    "increasedecreaseinnumberofordinarysharesissued": 6911710,
    "adjustmentsforsharebasedpayments": 867000,
    "cashflowsfromusedinoperations": -37900000,
    "adjustmentsfordepreciationandamortisationexpense": 4909000,
    "impairment": 44000,
    "othernoncashtransactions": -473000,
    "cashflowsfromusedinoperationsbeforechangesinworkingcapital": -32553000,
    "adjustmentsfordecreaseincreaseininventories": -416000,
    "adjustmentsfordecreaseincreaseintradeaccountreceivable": -5122000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 3973000,
    "cashflowsfromusedinoperatingactivities": -34118000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 2789000,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 1374000,
    "cashflowsusedinobtainingcontrolofsubsidiariesorotherbusinessesclassifiedasinvestingactivities": 25000000,
    "cashflowsfromusedininvestingactivities": -29163000,
    "proceedsfromborrowingsclassifiedasfinancingactivities": 34291000,
    "paymentoflongtermdebt": 10805000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 1358000,
    "paymentofinterest": -1412000,
    "interestsreceived": 125000,
    "cashflowsfromusedinfinancingactivities": 20841000,
    "netdecreaseincashandcashequivalents": -42440000,
    "cashandcashequivalentsclassifiedaspartofdisposalgroupheldforsale": 15503000,
    "effectofexchangeratechangesoncashandcashequivalents": -555000,
    "disclosureofstatusandprincipalactivitytextblock": "NOTE 1: Status and principal activity ",
    "loansborrowingsandleaseliabilitiestextblock": "NOTE 16: Loans, Borrowings, Leases obligationsand other financial liabilities ",
    "contractualobligationstextblock": "NOTE 17: Contractual obligations ",
    "retirementbenefitschemestextblock": "NOTE 23: Retirement benefit plans ",
    "principalauditfeesandservicestextblock": "NOTE 29: Principal audit fees and services ",
    "descriptionofaccountingpolicyforbasisofpreparationandstatementofcompliancetextblock": "Basis of preparation and statement of compliance",
    "descriptionofaccountingpolicyforconsolidationtextblock": "Basis of consolidation",
    "descriptionofaccountingpolicyforgoingconcerntextblock": "Going Concern",
    "useofestimatespolicytextblock": "Use of estimates and judgments",
    "newstandardsinterpretationsandamendmentspolicytextblock": "New Standards, Interpretations and Amendments ",
    "segmentinformationpolicytextblock": "Segment information",
    "rightofuseassetsandliabilitiespolicytextblock": "Right-of-use assets and liabilities",
    "descriptionofaccountingpolicyfortaxationtextblock": "Taxation",
    "descriptionofaccountingpolicyforsharecapitalpolicytextblock": "Share Capital",
    "descriptionofaccountingpolicyforfinancialassets": "Financial Assets",
    "descriptionofaccountingpolicyforfinancialliabilitiestextblock": "Financial Liabilities",
    "descriptionofaccountingpolicyforretirementbenefitschemesandemployeesavingsschemestextblock": "Retirement benefit plans and employee savings plans",
    "descriptionofaccountingpolicyforsharesbasedcompensationplansforpersonneldirectorsandbusinessassociatestextblock": "Share-based compensation plans for personnel, directors and business associates",
    "disclosureofacquisitionconsiderationtable": "      Cash     $25,000       Stock      5,000       GPS Contingent consideration      50,483       Total acquisition consideration     $80,483    ",
    "disclosureoffairvalueoftheidentifiableassetstable": "      Thousands    of $ As of December 31, 2022     Carrying value at acquisition date      Fair value adjustments      Fair value at acquisition date       Intangible assets IP / Brand            -       36,550       36,550       Intangible assets Customer relationships      -       8,007       8,007       Total identified assets      -       44,557       44,557       Goodwill      -       35,926       35,926       Acquisition price      -       -       80,483    ",
    "scheduleofrevenuetabletextblock": "      Thousandsof $ For the years ended December 31      2022       2021      2020       Services      36,965       21,937       18,064       Licenses      25       250       250       Royalties and other revenues      64       52       146       Total revenue      37,054       22,239       18,460    ",
    "scheduleofcostofgoodsservicessoldtabletextblock": "      Thousands of $ For the years ended December 31      2022       2021      2020       Cost of goods & services sold      17,835       11,675       10,416       Total cost of goods & services sold      17,835       11,675       10,416    ",
    "scheduleofotheroperatingincomeexpensesnettextblock": "      Thousands of $ For the years ended December 31      2022       2021      2020       Grant subsidies – The Netherlands1      5       382       0       Grant subsidies – USA      0       659       0       Fair value adjustments      515       176       118       Other operating income      39       53       0       Other operating expenses      0       (109)      0       Total other operating income, net      559       1,161       118    ",
    "scheduleofleaserecognizedtabletextblock": "      Thousands of $     2022      2021      2020       Depreciation expense      1,067       905       771       Interest expense on lease liabilities      314       229       93   ",
    "inventoriestabletextblock": "      Thousandsof $ For the years ended December 31     2022      2021       Raw materials and consumables      2,327       1,911       Total Inventories      2,327       1,911    ",
    "scheduleoftradereceivablestabletextblock": "      Thousandsof $ For the years ended December 31     2022      2021       Trade receivables      9,357       4,582       Total trade receivables      9,357       4,582    ",
    "scheduleofprepaidexpensesandothercurrentassetstabletextblock": "      Thousandsof $ For the years ended December 31       2022       2021       Prepayments      1,710       1,022       Deposits      101       89       Recoverable VAT      97       246       Grants to be received      54       235       Other      0       23       Total prepaid expenses and other current assets      1,962       1,615    ",
    "scheduleofcashandcashequivalenttabletextblock": "      Thousandsof $ For the years ended December 31      2022       2021       Cash and cash equivalents      15,503       58,498       Total cash and cash equivalents      15,503       58,498   ",
    "loansborrowingsleaseliabilitiestabletextblock": "      Thousandsof $ For the years ended December 31      2022       2021       Non-current loans and borrowings                    Loans      34,914       7,651       Lease liabilities (*)      3,091       2,624       Total non-current loans and borrowings      38,005       10,275    ",
    "scheduleofmaturityofloansandborrowingstabletextblock": "      Thousandsof $ For the years ended December 31      2022       2021       Loans                    Within one year      630       4,780       Years two to five      38,439       9,283                              Leases                      Within one year      1,551       1,127       Years two to five      2,330       3,094    ",
    "scheduleoffinancialinstrumentrelatedtotheinitialdrawdownfeetabletextblock": "      Thousandsof $ For the years ended December 31      2022       2021       Other financial liabilities                    Other non-currentfinancial liabilities      53,537       1,466       Other current financial liabilities      2,327       961       Total other financial liabilities      55,864       2,427    ",
    "scheduleoffairvalueadjustmentsrecognizedtabletextblock": "      Thousands of $ For the years ended December 31      2022       Decrease of contingent consideration Noviogendix      (632)      Increase of Kreos derivative financial instrument (“initial drawdown fee”)      116       Increase of GPS contingent consideration      2,398       Decrease of Innovatus embedded derivative convertible call option      (116)      Total fair value adjustment      1,766    ",
    "scheduleofleaseliabilitiestabletextblock": "      Thousands    of $     Lease    liabilities       For                                            the years ended December 31     2022      2021       Opening balance      3,464       2,774       Cash movements                      Repayment of lease liabilities      (1,358)      (1,057)      Non-cash movements                      Interest accretion      314       229       New leases      1,843       1,518       Closing balance      4,263       3,464   ",
    "scheduleofcontractualobligationstabletextblock": "      Thousands of $ For The Years ended December 31       2022       2021       Outstanding commitments for future minimum rent payments, which fall due as follows:                    Less than one year      156       215       Years 2-5      60       39       Total contractual obligations      216       254    ",
    "scheduleoftradeaccountspayabletabletextblock": "      Thousands of $ For The Years ended December 31      2022       2021       Trade accounts payable      5,061       3,192       Accruals for invoices to be received      5,117       4,263       Total trade accounts payable      10,178       7,455    ",
    "scheduleofothercurrentliabilitiestabletextblock": "      Thousandsof $ For The Years ended December 31      2022       2021       Payroll      3,932       2,703       Other accruals      53       32       Total other current liabilities      3,985       2,735   ",
    "scheduleofsharecapitalnumberofsharestabletextblock": "      Forthe Years ended December 31     2022      2021       Common shares      162,880,936       155,969,226       Total outstanding shares      162,880,936       155,969,226    ",
    "scheduleoftheoutstandingpotentialsharesfromwarrantsperpersonnelcategorytabletextblock": "      Category     2022      2021       Executive Director      3,950,000       2,950,000       Non-Executive Directors      248,000       272,000       Management team (excluding the Executive Director)      4,083,000       2,938,000       Other employees, consultants, and former service providers      3,976,780       2,757,625       Total outstanding at December 31      12,257,780       8,917,625     ",
    "disclosureofsharebasedcompensationexpenserecognizedinthestatementofcomprehensiveincomeexplanatory": "      Thousandsof $ Years ended December 31      2022       2021      2020       Share-based compensation      867       1,222       1,295       Cumulated Share-based compensation      11,474       10,607       9,385    ",
    "disclosureofwarrantstabletextblock": "            2022      2021      2020       Number of warrants exercised      0       0       0       Number of new warrants granted and accepted      2,200,000       2,200,000       1,183,000       Annualized IFRS cost for existing warrants     $863,000      $982,000      $596,000    ",
    "cashtransferred": 25000000,
    "stocktransferred": 5000000,
    "contingentconsiderationsrecognisedasofacquisitiondate": 50483000,
    "acquisitiondatefairvalueoftotalconsiderationtransferred": 80483000,
    "intangibleassetsacquiredbywayofgovernmentgrantatfairvalue": 36550000,
    "intangibleassetsipbrandfairvalueatacquisitiondate": 36550000,
    "intangibleassetscustomerrelationshipsfairvalueadjustments": 8007000,
    "intangibleassetscustomerrelationshipsfairvalueatacquisitiondate": 8007000,
    "identifiedassetsfairvalueadjustments": 44557000,
    "identifiedassetsfairvalueatacquisitiondate": 44557000,
    "goodwillfairvalueadjustments": 35926000,
    "goodwillfairvalueatacquisitiondate": 35926000,
    "acquisitionpricefairvalueatacquisitiondate": 80483000,
    "revenuefromsaleofgold": 37054000,
    "totalsegmentrevenue": 37054000,
    "purchasesofgoodsrelatedpartytransactions": 17835000,
    "totalcostofgoodsservicessold": 17835000,
    "keymanagementpersonnelcompensation": 2453000,
    "depreciationandamortisationexpenses": 2272000,
    "impairmentloss": 44000,
    "labconsumables": 713000,
    "patentexpenses": 430000,
    "externalresearchanddevelopmentcollaboratorfees": 783000,
    "clinicalvalidation": 584000,
    "otherexpensebynature": 278000,
    "keymanagementpersonnelcompensations": 19070000,
    "depreciationexpense": 1628000,
    "professionalfeesexpense": 5700000,
    "marketingexpenses": 2843000,
    "travelexpenses": 789000,
    "officesfacilitiesexpenses": 356000,
    "otherexpensebyfunction": 637000,
    "totalsellingandmarketingexpenses": 26582000,
    "personnelcost": 8995000,
    "depreciationandamortisationexpense": 965000,
    "professionalfeesexpenses": 7762000,
    "publiccompanyexpenses": 4025000,
    "officesfacilitiesexpense": 1142000,
    "tradeandotherpayablestorelatedparties": 47000,
    "otherexpense": 603000,
    "operatingexpense": 67000,
    "laboratorystaffheadcount": 19000,
    "smstaffheadcount": 101000,
    "gastaffheadcount": 71000,
    "totalnumberofemployees": 258000,
    "wagesandsalaries": 23066000,
    "socialsecuritycosts": 1684000,
    "otherlongtermbenefits": 724000,
    "insuranceexpense": 3167000,
    "othercosts": 1010000,
    "totalpersonnelcosts": 30518000,
    "interestincomeondebtinstrumentsheld": 125,
    "interestexpenseonborrowings": 660,
    "interestexpenseondebtinstrumentsissued": 1615,
    "interestexpenseonbankloansandoverdrafts": 361,
    "adjustmentsforgainslossesonchangeinfairvalueofderivatives": -2479,
    "proceedsfromcurrentborrowings": 1047,
    "otherfinancialloss": -107,
    "netfinancialresults": -6144,
    "taxexpenseincomeatapplicabletaxrate": -11011000,
    "deferredtaxassets": 11011000,
    "taxrateeffectfromchangeintaxrate": 0.25,
    "additionsotherthanthroughbusinesscombinationsreinsuranceassets": 35926000,
    "carryingvalue": 35926000,
    "descriptionofdiscountratesusedincurrentestimateofvalueinuse": 0.1495,
    "terminalgrowthrate": 0.02,
    "additionsotherthanthroughbusinesscombinationpropertyplantandequipment": -1374000,
    "acquisitionsthroughbusinesscombinationsintangibleassetsandgoodwill": 36600000,
    "grossvalueendingbalance": 64888000,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 3169000,
    "impairments": -44000,
    "accumulatedamortizationandimpairmentendingbalances": -18722000,
    "netvalue": 46166000,
    "propertyplantandequipmentsgrossvalue": 10482000,
    "propertyplantandequipmentaccumulateddepreciation": -6691000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 3791000,
    "propertyplantandequipmentgrossadditions": 2789000,
    "propertyplantandequipmentgrossdisposals": -258000,
    "exchangeratedifferencearisinggross": 83000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 673000,
    "disposalspropertyplantandequipment": 258000,
    "exchangeratedifferencearising": -79000,
    "rightofuseassetsgrossvalue": 8071000,
    "rightofuseassetsaccumulatedamortizationbeginning": -3968000,
    "rightofuseassetnetvalue": 4103000,
    "rightofuseassetsgrossadditions": 1827000,
    "rightofuseassetsgrossvalueexchangeratedifferences": -1000,
    "rightofuseassetsadditions": -1067000,
    "rightofuseassetsaccumulateddepreciationexchangeratedifferences": -3000,
    "propertyplantequipmentdepreciationexpense": 1067000,
    "interestexpenseonleaseliabilities": 314000,
    "noncurrentinventories": 2327000,
    "tradeandotherreceivables": 9357000,
    "tradereceivables": 9357000,
    "otherreceivables": 9357000,
    "currentprepayments": 1710000,
    "shorttermdepositsnotclassifiedascashequivalents": 101000,
    "recoverablevat": 97000,
    "receivablesfromsaleofproperties": 54000,
    "othercurrentassets": 1962000,
    "cashonhand": 15503000,
    "othercashandcashequivalents": 15503000,
    "loanspayablesnoncurrent": 34914000,
    "interestexpenseonleaseliability": 3091000,
    "totalnoncurrentloansandborrowings": 38005000,
    "loanspayablescurrent": 616000,
    "totalcurrentloansandborrowings": 1788000,
    "loanswithinoneyear": 630000,
    "loansyearstwotofive": 38439000,
    "leaseswithinoneyear": 1551000,
    "leasesyearstwotofive": 2330000,
    "financialliabilitiesatamortisedcost": 53537000,
    "otherfinancialliabilities": 55864000,
    "otherprovisions": 55864000,
    "loansandborrowingsrepaid": -10805000,
    "loansandborrowingsreceived": 34291000,
    "gpscontingentconsideration": 52881000,
    "recognitionofinnovatusembeddedderivativeconvertiblecalloption": -1026000,
    "kreoseffectiveinterestrateadjustmentandextinguishmentcosts": 1328000,
    "interestrevenuecalculatedusingeffectiveinterestmethod": 660000,
    "foreignexchangerateimpactother": -35000,
    "gainslossesonfinancialassetsatfairvaluethroughprofitorlossclassifiedasheldfortrading": 1963000,
    "decreaseofcontingentconsiderationnoviogendix": -632000,
    "increaseofkreosderivativefinancialinstrumentinitialdrawdownfee": 116000,
    "increaseofgpscontingentconsideration": 2398000,
    "decreaseofinnovatusembeddedderivativeconvertiblecalloption": -116000,
    "totalfairvalueadjustment": 1766000,
    "leaseliabilities": 4263000,
    "repaymentsofborrowingsclassifiedasfinancingactivities": 1358000,
    "interestexpense": 90000,
    "cashoutflowforleases": 1843000,
    "ontractualobligationlessthanoneyear": 156000,
    "contractualobligationssecondtofifthyear": 60000,
    "contractualobligations": 216000,
    "tradeandotherpayablestotradesuppliers": 5061000,
    "accrualsforinvoicestobereceived": 5117000,
    "tradeandothercurrentpayables": 10178000,
    "payroll": 3932000,
    "otheraccruals": 53000,
    "totalothercurrentliabilities": 3985000,
    "financialassets": 24860000,
    "noviogendixcontingentconsideration": 1182000,
    "innovatusderivativeinstrument": 910000,
    "kreosderivativeinstrument": 891000,
    "financialliabilitiesatfairvalue": 55864000,
    "loansandborrowingss": 35530000,
    "leaseliabilitiesoffinancialinstruments": 4263000,
    "tradeandotherpayables": 10178000,
    "subtotalfinancialliabilitiesatamortizedcost": 49971000,
    "financialliabilities": 105835000,
    "cashequivalents": 1801000,
    "deferredacquisitioncostsarisingfrominsurancecontracts": 54063000,
    "currentderivativefinancialliabilities": 1026000,
    "increasedecreasethroughforeignexchangeandothermovementsfinancialassets": -35000,
    "fairvaluechangesthroughprofitandloss": 1963000,
    "profitlossattributabletoownersofparent": -44044000,
    "basicearningslosspersharefromdiscontinuedoperations": -0.28,
    "weightedaverageshares": 158658165,
    "dilutedearningslosspersharefromdiscontinuedoperations": -0.28,
    "adjustedweightedaverageshares": 158658165,
    "tradeandotherpayablesundiscountedcashflows": 10178000,
    "loansandadvancestocustomers": 35530000,
    "grossleaseliabilities": 4263000,
    "nonderivativeundiscountedcashflowstotal": 49971000,
    "numberofsharesauthorised": 162880936,
    "totaloutstandingshares": 162880936,
    "sharecapitalsituationatending": 133454000,
    "issuancepremiumsituationatending": 153177000,
    "sharecapitalissuancesharesone": 5000000,
    "sharecapitalasperstatutoryaccounts": 148419000,
    "capitalincreasecosts": -14965000,
    "sharecapitalunderifrs": 133454000,
    "issuancepremiums": 153177000,
    "sharecapitalandissuancepremium": 286631000,
    "numbersofshareoutstanding": 12257780,
    "numberofwarrantcancelledforfeitedduringtheyear": -590345,
    "numberofwarrantgrantedduringtheyear": 3930500,
    "outstandingwarrantsbeginning": 3930500,
    "weightedaverageexercisepricegranted": 0.68,
    "outstandingpotentialsharesfromexerciseofwarrantsbeginning": 3930500,
    "weightedaverageexercisepriceperpotentialsharegranted": 0.68,
    "outstandingwarrantsending": 12257780,
    "outstandingweightedaverageexercisepriceending": 1.23,
    "outstandingpotentialsharesfromexerciseofwarrantsending": 12257780,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 1.23,
    "sharwbasedpaymentoutstandingwarrantsexercisableshares": 5220520,
    "weightedaverageexercisepriceoutstandingexercisable": 1.63,
    "outstandingpotentialsharesfromexerciseofwarrantsexercisable": 5220520,
    "weightedaverageexercisepriceperpotentialshareoutstandingexercisable": 1.63,
    "executivedirectorinshares": 3950000,
    "nonexecutivedirectors": 248000,
    "managementteamexcludingtheexecutivedirector": 4083000,
    "otheremployeesconsultantsandformerserviceproviders": 3976780,
    "totaloutstanding": 12257780,
    "sharebasedcompensation": 867000,
    "cumulatedsharebasedcompensation": 11474000,
    "numberofwarrantsgrantedtobelgianfenef": 20000,
    "numberofwarrantsgrantedtootherbenef": 15000,
    "exerciseprice": 128,
    "expectedstockpricevolatility": 51.57,
    "riskfreeinterestrate": 0.024,
    "expecteddurationmonthstobelgianbenef": 69.67,
    "expecteddurationmonthstootherbenefindollars": 63.65,
    "numberofmanagementmembersandexecutivedirectors": 4,
    "shorttermemployeebenefitsexpense": 1550000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 54000,
    "otherfinancecost": 219000,
    "increasedecreaseinnetdefinedbenefitliabilityasset": 1822000,
    "ifrssharebasedcompensationexpense": 863000,
    "numberofwarrantsofferedinshares": 2200000,
    "cumulativeoutstandingwarrants": 8088000,
    "exercisablewarrants": 3618642,
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 2200000000,
    "financialassetsatfairvalue": 863000000,
    "addressofregisteredofficeofentity": "Transistorweg 5, 6534 AT Nijmegen, The Netherlands",
    "incorporationdate": "October 18, 2006",
    "countryofincorporationdate": "September 18, 2015",
    "numberofemployee": "12 at December 31, 2022, 11 at December 31, 2021 and 9 at December 31, 2020.",
    "auditfeeforstatutoryandconsolidatedfinancial": 239000,
    "otherauditfees": 191000,
    "auditrelatedandotherservicesipointheusa": 42000,
    "totalstatutoryauditorperformance": 472000,
    "collegeofamericanpathologists": 13448,
    "accumulatedothercomprehensiveincome": 288300000,
    "netloss": 44000000,
    "netcashusedinoperatingactivities": 34100000,
    "cashequivalent": 15500000,
    "aggregateearnoutamount": 70000000,
    "netdebt": 180000,
    "carriedforwardamount": 285300000,
    "increasedecreaseindeferredtaxliabilityasset": 71300000,
    "goodwillamount": 35900000,
    "impairmentterm": "five years",
    "perpetualgrowthrate": 0.02,
    "interestrate": 10,
    "estimatedfinancialeffectofcontingentliabilities": 52900000,
    "adjustmentsforgainslossesonfairvalueadjustmentinvestmentproperty": 2400000,
    "discountratepercentage": 0.1216,
    "totalcost": 724000,
    "redesignatedfinancialliabilityatfairvaluethroughprofitorloss": 630000,
    "estimatedamount": 891000,
    "estimatedvalue": 900000,
    "intellectualproperty": 15,
    "customers": 6.5,
    "capitalizeddevelopmentcosts": 5,
    "estimatedusefullifedescription": "Property, plant and equipment are stated at historicalcost less accumulated depreciation and impairment. Repair and maintenance costs are charged to the income statement as incurred. Gainsand losses on the disposal of property, plant and equipment are included in other income or expenses. Depreciation is charged to writeoff the cost or valuation of assets over their useful lives, using the straight-line method, on the following basis: ",
    "depreciationperiodsrange": 6,
    "percentageofbuildings": 0.11,
    "percentageofvehicles": 0.0375,
    "percentageofmaterials": 0.06,
    "officeequipment": 5000,
    "tradereceivable": "one year",
    "outstandingaggregateprincipalamount": 0.15,
    "weightedvaluespercent": 1.5,
    "aggregatepurchaseprice": 100000000,
    "settledliabilitiescontingentliabilitiesrecognisedinbusinesscombination": 5000000,
    "americandepositarysharesissued": 691171,
    "parvaluepershare": 7.23,
    "sharesoutstandingpercentage": 0.05,
    "disposalsintangibleassetsandgoodwill": 35900000,
    "acquisitiondatefairvalueofequityinterestinacquireeheldbyacquirerimmediatelybeforeacquisitiondate": 44600000,
    "royaltypercentage": 0.0956,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": 4.3,
    "discountrateusedinvaluation": 0.1495,
    "contingentconsiderationrecognisedasofacquisitiondate": 52900000,
    "acquisitionrelatedcostsrecognisedasexpensefortransactionrecognisedseparatelyfromacquisitionofassetsandassumptionofliabilitiesinbusinesscombination": 3700000,
    "otherrevenue": 27700000,
    "loansandreceivables": 35000000,
    "debtfacilityamount": 9000000,
    "percentageofentitysrevenue": 0.67,
    "insurancerevenuerate": 0.59,
    "rmainingrevenue": 4900000,
    "customergeneratingover": 0.1,
    "totalrevenue": 15800000,
    "concludedagreementsdescription": "the Company had concludedagreements with 129 commercial payors for Confirm mdx (2021: 119; 2020: 107) and 62 commercial payors for Select mdx (2021: 54; 2020:42).",
    "segmentrevenuedescription": "the Company earned 99.8% (2021: 98.6%;2020: 97.9%) of its revenue from external customers from its clinical laboratory testing services and out-licensing of intellectual property.In 2022, the clinical laboratory testing in the U.S. CLIA laboratory represented 99% of the Company’s revenue (2021: 97%; 2020:95%), while the out-licensing of intellectual property revenue in Europe represented less than 1% (2021: 1.5%; 2020: 3%).",
    "noncurrentasset": 0.07,
    "sellingexpense": 8800000,
    "generalandadministrativeexpenses": 9400000,
    "administrativeexpense": 3700000,
    "contingentconsiderationamount": 526000,
    "interestchargesandextinguishmentexpenses": 1600000,
    "deferredtaxassetwhenutilisationisdependentonfuturetaxableprofitsinexcessofprofitsfromreversaloftaxabletemporarydifferencesandentityhassufferedlossinjurisdictiontowhichdeferredtaxassetrelates": 285300000,
    "deferredtaxasset": 71300000,
    "applicabletaxrate": 0.25,
    "taxcreditcarryforwardexpirationperiod": 2021,
    "incometaxrelatingtochangesinfairvalueoffinancialliabilityattributabletochangeincreditriskofliabilityofothercomprehensiveincome": 402000,
    "goodwillterm": 5,
    "fairvalueofpropertyplantandequipmentmateriallydifferentfromcarryingamount": 39800000,
    "percentageofreasonablypossibleincreaseinunobservableinputassets": 0.01,
    "impairmentamount": 12500000,
    "growthratepercentage": 0.01,
    "decreaseinimpairmentamount": 8600000,
    "discountrate": 0.1881,
    "recoverableamountofassetorcashgeneratingunit": 8000000,
    "capitalizeddevelopmentexpenses": 1000000,
    "depreciationpropertyplantandequipment": 1700,
    "leaseholdsimprovements": 713000,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": 5,
    "additionstorightofuseassets": 1800000,
    "costofinventoriesrecognisedasexpenseduringperiod": 3600000,
    "descriptionofloanaccrueinterest": "The loans accrue interest at a floating per annumrate equal to the sum of (a) the greater of (i) the prime rate published in The Wall Street Journal in the “Money Rates”section or (ii) 4.00%, plus (b) 4.25%, and require interest-only payments for the initial four years.",
    "percentageofoutstandingprincipalamount": 0.15,
    "loanprice": 11.21,
    "totalloan": 0.01,
    "endofloanfee": 67500,
    "fixedrate": 0.15,
    "debtfacilitypecentage": 0.6482,
    "principalamount": 9000000,
    "totalamount": 10800000,
    "convertibledebts": 202500,
    "derivativefinancialliabilitiesheldforhedging": 891000,
    "capitalamount": 206000,
    "incurredamount": 1800000,
    "bankdebtinstrumentsheld": 9000000,
    "percentageofprincipalamountoftheinitialconvertibleloan": 0.25,
    "firstdiscretionaryconvertibleloan": 180000,
    "seconddiscretionaryconvertibleloan": 202500,
    "grossloancommitments": 45000000,
    "borrowingsinterestrate": 0.1216,
    "outstandingamount": 1600000,
    "earnoutpayable": 40000000,
    "noncurrentderivativefinancialliabilities": 52900000,
    "noncurrentfinancialliabilities": 910000,
    "feeandcommissionexpense": 630000,
    "dividendspaidordinarysharespershare": 0.85,
    "initialconvertibleloanpercentage": 1.5,
    "fairvalueamount": 891000,
    "propertyplantandequipmentcarryingamountatcostofrevaluedassets": 5000,
    "variableinterestrate": 0.0425,
    "interestratepercentage": 0.01,
    "derivativefinancialliabilities": 945000,
    "sharepriceconversionpercentage": 1.5,
    "issuesfairvaluemeasurementassets": 910000,
    "numberofcustomers": 1000,
    "noncurrentreceivables": 9400000,
    "creditriskcashequivalents": 15500000,
    "loanagreementterm": 60,
    "loanagreementtotalamount": 35000000,
    "borrowingsadjustmenttointerestratebasis": 0.0425,
    "increaseprimerate": 0.0025,
    "shorttermdepositsclassifiedascashequivalents": 1100000,
    "exchangerate": 0.1,
    "loanagreements": 2,
    "numberofleases": 11,
    "descriptionofsharesoutstanding": "●",
    "debtsinstrumentterm": "ten years",
    "cumulativetranchespercentage": 0.25,
    "vestininstalmentpercentage": 0.25,
    "firsttranchepercentage": 0.25,
    "nonvestedprice": 1.23,
    "contractuallife": 7.31,
    "expectedvolatilityterm": "two years",
    "directorsremunerationexpense": 876000,
    "expectedreimbursementotherprovisions": 23000,
    "reimbursementforexpenses": 314000,
    "currentheldtomaturityinvestments": 2200000,
    "fairvalueofacquiredreceivables": 1200000,
    "estimatedfinancialeffectofcontingentassets": 50500000,
    "usefullifemeasuredasperiodoftimebiologicalassetsatcost": "three years",
    "entityregistrantname": "MDxHealth SA ",
    "tradingsymbol": "MDXH",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "amendmentflag": "false",
    "entitycentralindexkey": 1872529,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-40996",
    "entityaddresscountry": "CA",
    "entityaddressaddressline1": "15279 Alton Parkway",
    "entityaddresspostalzipcode": 92618,
    "entityaddresscityortown": "Irvine",
    "entityincorporationstatecountrycode": "Belgium",
    "contactpersonnelname": "Michael McGarrity",
    "entityaddressaddressline2": "Suite 100",
    "cityareacode": "+1 949",
    "localphonenumber": "812-6979",
    "security12btitle": "Ordinary shares, no par value*",
    "securityexchangename": "Nasdaq",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorname": "BDO Réviseurs d’EntreprisesSRL",
    "auditorlocation": "Zaventem, Belgium",
    "auditorfirmid": 1432
  },
  {
    "date": "2021-12-31",
    "symbol": "MDXH",
    "period": "FY",
    "services": 21937000,
    "licenses": 250000,
    "royaltiesandotherrevenues": 52000,
    "revenue": 741000,
    "costofsales": 7778000,
    "grossprofit": 10564000,
    "researchanddevelopmentexpense": 6673000,
    "salesandmarketingexpense": 17744000,
    "generalandadministrativeexpense": 14149000,
    "otheroperatingincomeexpense": -109000,
    "profitlossfromoperatingactivities": -26841000,
    "financeincome": 11000,
    "financecosts": 2172000,
    "profitlossbeforetax": -29002000,
    "profitloss": -29002000,
    "basicearningslosspershare": -0.24,
    "gainslossesonexchangedifferencesontranslationnetoftax": 264000,
    "totalothercomprehensiveincomeloss": 264000,
    "comprehensiveincome": 264000,
    "intangibleassetsotherthangoodwill": 3448000,
    "propertyplantandequipment": 1671000,
    "rightofuseassets": 3347000,
    "noncurrentassets": 8466000,
    "inventories": 1911000,
    "tradeandothercurrentreceivables": 4582000,
    "prepaidexpensesandothercurrentassets": 1615000,
    "cashandcashequivalents": 58498000,
    "currentassets": 66606000,
    "assets": 75072000,
    "issuedcapital": 128454000,
    "sharepremium": 153177000,
    "retainedearnings": -244302000,
    "reserveofsharebasedpayments": 10607000,
    "translationreserve": -1037000,
    "equity": -1037000,
    "loansandborrowings": 7651000,
    "noncurrentleaseliabilities": 2624000,
    "othernoncurrentfinancialliabilities": 1466000,
    "noncurrentliabilities": 11741000,
    "currentportionoflongtermborrowings": 4441000,
    "currentleaseliabilities": 840000,
    "tradeandothercurrentpayablestotradesuppliers": 7455000,
    "othercurrentliabilities": 2735000,
    "othercurrentfinancialliabilities": 961000,
    "currentliabilities": 16432000,
    "liabilities": 28173000,
    "equityandliabilities": 75072000,
    "numberofsharesoutstanding": 281631,
    "othercomprehensiveincome": 264000,
    "issueofequity": 75339000,
    "increasedecreaseinnumberofordinarysharesissued": 75339,
    "deductionoftransactioncosts": -6773000,
    "deductionoftransactioncostsshares": -6773,
    "adjustmentsforsharebasedpayments": 1222000,
    "cashflowsfromusedinoperations": -26841000,
    "adjustmentsfordepreciationandamortisationexpense": 3036000,
    "othernoncashtransactions": -325000,
    "cashflowsfromusedinoperationsbeforechangesinworkingcapital": -22908000,
    "adjustmentsfordecreaseincreaseininventories": 413000,
    "adjustmentsfordecreaseincreaseintradeaccountreceivable": -1383000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 1330000,
    "cashflowsfromusedinoperatingactivities": -22548000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 896000,
    "interestreceivedclassifiedasinvestingactivities": 11000,
    "cashflowsfromusedininvestingactivities": -885000,
    "proceedsfromissuingshares": 68566000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 1057000,
    "paymentofinterest": -1011000,
    "cashflowsfromusedinfinancingactivities": 66498000,
    "netdecreaseincashandcashequivalents": 43065000,
    "cashandcashequivalentsclassifiedaspartofdisposalgroupheldforsale": 58498000,
    "effectofexchangeratechangesoncashandcashequivalents": -520000,
    "disclosureofstatusandprincipalactivitytextblock": "NOTE1: Status and principal activity ",
    "loansborrowingsandleaseliabilitiestextblock": "NOTE14: Loans, Borrowings, Leases obligations and other financial liabilities ",
    "contractualobligationstextblock": "NOTE15: Contractual obligations ",
    "retirementbenefitschemestextblock": "NOTE21: Retirement benefit schemes ",
    "principalauditfeesandservicestextblock": "NOTE26: Principal audit fees and services ",
    "descriptionofaccountingpolicyforbasisofpreparationandstatementofcompliancetextblock": "Basis of preparation and statement of compliance",
    "descriptionofaccountingpolicyforconsolidationtextblock": "Basis of consolidation",
    "descriptionofaccountingpolicyforgoingconcerntextblock": "Going Concern",
    "useofestimatespolicytextblock": "Use of estimates and judgments",
    "newstandardsinterpretationsandamendmentspolicytextblock": "New Standards, Interpretations and Amendments ",
    "rightofuseassetsandliabilitiespolicytextblock": "Right-of-use assets and liabilities",
    "descriptionofaccountingpolicyfortaxationtextblock": "Taxation",
    "descriptionofaccountingpolicyforsharecapitalpolicytextblock": "Share capital",
    "descriptionofaccountingpolicyforfinancialassets": "Financial Assets",
    "descriptionofaccountingpolicyforfinancialliabilitiestextblock": "Financial Liabilities",
    "descriptionofaccountingpolicyformeasurementoninitialrecognitiontextblock": "Measurement on initial recognition",
    "descriptionofaccountingpolicyforsubsequentmeasurements": "Subsequent measurement",
    "descriptionofaccountingpolicyforretirementbenefitschemesandemployeesavingsschemestextblock": "Retirement benefit schemes and employee savings schemes",
    "descriptionofaccountingpolicyforsharesbasedcompensationplansforpersonneldirectorsandbusinessassociatestextblock": "Share-based compensation plans for personnel, directors and business associates",
    "scheduleofrevenuetabletextblock": "      Thousands of $ For the years ended December 31     2021      2020      2019       Services      21,937       18,064       11,443       Licenses      250       250       250       Royalties and other revenues     52      146      92       Total revenue      22,239       18,460       11,785    ",
    "scheduleofcostofgoodsservicessoldtabletextblock": "      Thousands of $ For the years ended December 31     2021      2020      2019       Cost of goods & services sold     11,675      10,416      11,755       Total cost of goods & services sold      11,675       10,416       11,755    ",
    "scheduleofotheroperatingincomeexpensesnettextblock": "      Thousands of $ For the years ended December 31     2021      2020      2019       Grant subsidies – The Netherlands1      382       0       0       Grant subsidies – USA      659       0       0       Fair value adjustments      176       118       (48)      Impairment      0       0       (1,145)      Other operating income      53       0       1       Other operating expenses     (109)     0      (5)      Total other operating income (expense), net      1,161       118       (1,197)   ",
    "scheduleoffinanceincomeexpensestabletextblock": "      Thousands of $ For the years ended December 31     2021      2020      2019       Interest income      11       4       10       Interest on loans and leases      (1,875)      (1,227)      (318)      Fair value adjustments      (194)      (118)      (104)      Other financial loss     (103)     (198)     (94)      Net financial results      (2,161)      (1,539)      (506)   ",
    "scheduleofleaserecognizedtabletextblock": "      Thousands    of $     2021      2020      2019       Depreciation    expense      905       771       751       Interest    expense on lease liabilities      229       93       88   ",
    "inventoriestabletextblock": "      Thousands of $ For the years ended December 31     2021      2020       Raw materials and consumables      1,911       2,324       Total Inventories      1,911       2,324    ",
    "scheduleoftradereceivablestabletextblock": "      Thousands of $ For the years ended December 31     2021      2020       Trade receivables      4,582       3,771       Total trade receivables      4,582       3,771    ",
    "scheduleoftotalaccountsreceivablebalancewiththeclaimdatetabletextblock": "      A/R by claim date       Months              Thousands of $ For the years ended December 31, 2020     1-3 months      4-6 months      7-12 months      Not due      Total       ConfirmMDx      1,570       716       1,034               3,320       SelectMDx      80       62       115       59       316       Other     114      2      2      17      135       Total Trade Receivables      1,764       780       1,151       76       3,771    ",
    "scheduleofprepaidexpensesandothercurrentassetstabletextblock": "      Thousands of $ For the years ended December 31     2021      2020       Prepayments      1,022       868       Deposits      89       52       Recoverable VAT      246       123       Grants to be received      235       0       Other     23       0       Total prepaid expenses and other current assets      1,615       1,043    ",
    "scheduleofcashandcashequivalenttabletextblock": "      Thousands of $ For the years ended December 31     2021      2020       Cash and cash equivalents      58,498       15,953       Total cash and cash equivalents      58,498       15,953    ",
    "loansborrowingsleaseliabilitiestabletextblock": "      Thousands of $ For the years ended December 31     2021      2020       Non-current loans and borrowings                    Loans (*)      7,490       10,279       Convertible loans      161       0       Lease liabilities (**)      2,624       2,017       Total non-current loans and borrowings      10,275       12,296    ",
    "scheduleofmaturityofloansandborrowingstabletextblock": "      Thousands of $ For the years ended December 31     2021      2020       Loans (including convertible loan)                    Within one year      4,780       3,644       Years two to five      9,283       11,736                              Leases                      Within one year      1,127       1,040       Years two to five      3,094       2,414    ",
    "scheduleoffinancialinstrumentrelatedtotheinitialdrawdownfeetabletextblock": "      Thousands of $ For the years ended December 31     2021      2020       Other financial liabilities                    Other non-current financial liabilities1      1,466       690       Other current financial liabilities      961       909       Total other financial liabilities      2,427       1,599    ",
    "scheduleofleaseliabilitiestabletextblock": "      Thousands of $     Lease liabilities       For the years ended December 31     2021      2020       Opening balance      2,774       1,385       Cash movements                      Repayment of lease liabilities      (1,057)      (831)      Non-cash movements                      Interest accretion      229       89       New leases      1,518       2,131       Closing balance      3,464       2,774   ",
    "scheduleofcontractualobligationstabletextblock": "      Thousands of $ For the years ended December 31     2021      2020       Outstanding commitments for future minimum rent payments, which fall due as follows:                    Less than one year      215       113       Years 2-5      39       112       Total contractual obligations      254       225    ",
    "scheduleoftradeaccountspayabletabletextblock": "      Thousands of $ For the years ended December 31     2021      2020       Trade accounts payable      3,192       2,903       Accruals for invoices to be received      4,263       2,417       Total trade accounts payable      7,455       5,320    ",
    "scheduleofothercurrentliabilitiestabletextblock": "      Thousands of $ For the years ended December 31     2021      2020       Payroll      2,703       2,539       Other accruals      32       678       Total other current liabilities      2,735       3,217    ",
    "scheduleofsharecapitalnumberofsharestabletextblock": "      For the years ended December 31     2021      2020       Common shares      155,969,226       90,691,449       Total outstanding shares      155,969,226       90,691,449    ",
    "scheduleoftheoutstandingpotentialsharesfromwarrantsperpersonnelcategorytabletextblock": "      Category     2021      2020       Executive Director      2,950,000       1,950,000       Non-Executive Directors      272,000       272,000       Management team (excluding the Executive Director)      2,938,000       1,738,000       Other employees, consultants, and former service providers      2,757,625       1,806,093       Total outstanding at December 31      8,917,625       5,766,093    ",
    "disclosureofsharebasedcompensationexpenserecognizedinthestatementofcomprehensiveincomeexplanatory": "      Thousands of $ Years ended December 31     2021      2020      2019       Share-based compensation      1,222       1,295       872       Cumulated Share-based compensation      10,607       9,385       8,090    ",
    "scheduleofnumberofwarrantsthatwereexercisedtabletextblock": "            2021      2020      2019       Number of warrants exercised      0       0       0       Number of new warrants granted and accepted      2,200,000       1,183,000       2,330,000       Annualized IFRS cost for existing warrants     $982,000      $596,000      $34,000    ",
    "scheduleofwhollyowneddirectsubsidiariestabletextblock": "    MDxHealth    Inc.          Address     15279 Alton Parkway – Suite 100 – Irvine, CA 92618    Incorporation Date     April 14, 2003    Number of employees     176 at December 31,2021, 163 at December 31, 2020 and 158 at December 31, 2019. ",
    "otherrevenue": 22239000,
    "product": 13615000,
    "totalsegmentrevenue": 22239000,
    "purchasesofgoodsrelatedpartytransactions": 11675000,
    "totalcostofgoodsservicessold": 11675000,
    "keymanagementpersonnelcompensation": 1949000,
    "depreciationandamortisationexpenses": 1360000,
    "labconsumables": 793000,
    "patentexpenses": 577000,
    "externalresearchanddevelopmentcollaboratorfees": 1020000,
    "clinicalvalidation": 842000,
    "otherexpensebynature": 132000,
    "keymanagementpersonnelcompensations": 13402000,
    "depreciationexpense": 796000,
    "professionalfeesexpense": 523000,
    "marketingexpenses": 1761000,
    "travelexpenses": 340000,
    "officesfacilitiesexpenses": 436000,
    "otherexpensebyfunction": 486000,
    "sellingexpense": 17744000,
    "personnelcost": 9009000,
    "depreciationandamortisationexpense": 880000,
    "professionalfeesexpenses": 2018000,
    "officesfacilitiesexpense": 845000,
    "tradeandotherpayablestorelatedparties": 152000,
    "boardfeesexpenses": 314000,
    "otherexpense": 931000,
    "managementheadcount": 4000,
    "laboratorystaffheadcount": 14000,
    "smstaffheadcount": 111000,
    "gastaffheadcount": 62000,
    "totalnumberofemployees": 191000,
    "wagesandsalaries": 18150000,
    "socialsecuritycosts": 1257000,
    "otherlongtermbenefits": 594000,
    "insuranceexpense": 2324000,
    "othercosts": 813000,
    "totalpersonnelcosts": 24360000,
    "interestincomeondebtinstrumentsheld": 11000,
    "interestexpenseonbankloansandoverdrafts": 1875000,
    "adjustmentsforgainslossesonfairvalueadjustmentinvestmentproperty": -194000,
    "otherfinancialloss": -103000,
    "netfinancialresults": -2161000,
    "taxexpenseincomeatapplicabletaxrate": 7251000,
    "deferredtaxassets": 3000000,
    "taxrateeffectfromchangeintaxrate": 0.25,
    "intangibleassetsbeginningbalance": -17199000,
    "additionsotherthanthroughbusinesscombinationpropertyplantandequipment": 1610000,
    "accumulatedamortizationandimpairment": -18809000,
    "netvalue": 3448000,
    "grossvalue": 22257000,
    "propertyplantandequipmentsgrossvalue": 7868000,
    "propertyplantandequipmentaccumulateddepreciation": -6197000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 1671000,
    "propertyplantandequipmentgrossadditions": 1219000,
    "propertyplantandequipmentgrossdisposals": -2000,
    "exchangeratedifferencearisinggross": -312000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 521000,
    "disposalspropertyplantandequipment": 2000,
    "exchangeratedifferencearising": 312000,
    "rightofuseassetsgrossvalue": 6245000,
    "rightofuseassetsaccumulatedamortizationbeginning": -2898000,
    "rightofuseassetnetvalue": 3347000,
    "rightofuseassetsgrossadditions": 1518000,
    "rightofuseassetsadditions": -905000,
    "propertyplantequipmentdepreciationexpense": 905000,
    "interestexpenseonleaseliabilities": 229000,
    "noncurrentinventories": 1911000,
    "otherinventoriesspareparts": 1911000,
    "tradeandotherreceivables": 4582000,
    "tradereceivables": 4582000,
    "otherreceivables": 4582000,
    "currentprepayments": 1022000,
    "shorttermdepositsnotclassifiedascashequivalents": 89000,
    "recoverablevat": 246000,
    "receivablesfromsaleofproperties": 235000,
    "otherpayables": 23000,
    "othercurrentassets": 1615000,
    "cashonhand": 58498000,
    "othercashandcashequivalents": 58498000,
    "loanspayablesnoncurrent": 7490000,
    "convertibleloansnoncurrent": 161000,
    "interestexpenseonleaseliability": 2624000,
    "totalnoncurrentloansandborrowings": 10275000,
    "loanspayablescurrent": 4170000,
    "convertibleloanscurrent": 271000,
    "totalcurrentloansandborrowings": 5281000,
    "loanswithinoneyear": 4780000,
    "loansyearstwotofive": 9283000,
    "leaseswithinoneyear": 1127000,
    "leasesyearstwotofive": 3094000,
    "financialliabilitiesatamortisedcost": 1466000,
    "otherfinancialliabilities": 2427000,
    "otherborrowings": 2427000,
    "amountofreclassifications": 773000,
    "interestrevenuecalculatedusingeffectiveinterestmethod": 194000,
    "foreignexchangerateimpactothers": -59000,
    "gainslossesonfinancialassetsatfairvaluethroughprofitorlossclassifiedasheldfortrading": 96000,
    "leaseliabilities": 3464000,
    "repaymentsofborrowingsclassifiedasfinancingactivities": 1057000,
    "interestexpense": 229000,
    "cashoutflowforleases": 1518000,
    "ontractualobligationlessthanoneyear": 215000,
    "contractualobligationssecondtofifthyear": 39000,
    "contractualobligations": 254000,
    "tradeandotherpayablestotradesuppliers": 3192000,
    "tradeandotherreceivable": 4263000,
    "tradeandothercurrentpayables": 7455000,
    "payroll": 2703000,
    "otheraccruals": 32000,
    "totalothercurrentliabilities": 2735000,
    "financialassets": 63080000,
    "otherfinancialliabilitiess": 1617000,
    "otherfinancialliabilities1": "Level 3",
    "derivativefinancialliabilityforkreosdrawdownfees": 810000,
    "derivativefinancialliabilityforkreosdrawdownfee": "Level 3",
    "financialliabilitiesatfairvalue": 2427000,
    "loansandborrowingss": 12092000,
    "loansandborrowings1": "Level 2",
    "leaseliabilitiesoffinancialinstruments": 3464000,
    "tradeandotherpayables": 7455000,
    "subtotalfinancialliabilitiesatamortizedcost": 23011000,
    "financialliabilities": 25438000,
    "cashequivalents": 810000,
    "deferredacquisitioncostsarisingfrominsurancecontracts": 1617000,
    "reclassificationintoheldtomaturityinvestments": 773000,
    "effectiveinterestrateadjustment": 194000,
    "increasedecreasethroughforeignexchangeandothermovementsfinancialassets": -59000,
    "fairvaluechangesthroughprofitandloss": -176000,
    "profitlossattributabletoownersofparent": -29002000,
    "dilutedearningslosspershare": -0.24,
    "weightedaveragenumberofsharesforbasicanddilutedeps": 121935741,
    "tradeandotherpayablesundiscountedcashflows": 7455,
    "loansandadvancestocustomers": 12092,
    "grossleaseliabilities": 3464,
    "nonderivativeundiscountedcashflowstotal": 23011,
    "numberofsharesauthorised": 155969226,
    "totaloutstandingshares": 155969226,
    "sharecapitalsituationatending": 128454000,
    "issuancepremiumsituationatending": 153177000,
    "sharecapitalissuanceofshares": 23632000,
    "issuancepremiumissuanceofshares": 4693000,
    "sharecapitalissuancesharesone": 28106000,
    "issuancepremiumissuancesharesone": 12135000,
    "sharecapitalissuance": 24412000,
    "sharecapitalasperstatutoryaccount": 143419000,
    "capitalincreasecost": -14965000,
    "sharecapitalunderamount": 128454000,
    "unearnedpremiums": 153177000,
    "sharecapitalandissuancepremiums": 281631000,
    "numbersofshareoutstanding": 8917625,
    "numberofwarrantcancelledforfeitedduringtheyear": -304968,
    "numberofwarrantgrantedduringtheyear": 3456500,
    "outstandingwarrantsbeginning": 1.37,
    "outstandingweightedaverageexercisepricebeginning": 3456500,
    "outstandingpotentialsharesfromexerciseofwarrantsbeginning": 1.37,
    "outstandingwarrantsending": 1.53,
    "outstandingweightedaverageexercisepriceending": 8917625,
    "outstandingpotentialsharesfromexerciseofwarrantsending": 1.53,
    "sharwbasedpaymentoutstandingwarrantsexercisableshares": 2.08,
    "outstandingweightedaverageexercisepriceexercisable": 3093499,
    "outstandingpotentialsharesfromexerciseofwarrantsexercisable": 2.08,
    "executivedirectorinshares": 2950000,
    "nonexecutivedirectors": 272000,
    "managementteamexcludingtheexecutivedirector": 2938000,
    "otheremployeesconsultantsandformerserviceproviders": 2757625,
    "totaloutstanding": 8917625,
    "sharebasedcompensation": 1222000,
    "cumulatedsharebasedcompensation": 10607000,
    "numberofwarrantsgrantedtobelgianfenef": 20000,
    "numberofwarrantsgrantedtootherbenef": 600000,
    "exerciseprice": 128,
    "expectedstockpricevolatility": 51.57,
    "riskfreeinterestrate": 0.0004,
    "expecteddurationmonthstobelgianbenef": 44.78,
    "expecteddurationmonthstootherbenefindollars": 26.79,
    "numberofmanagementmembersandexecutivedirectors": 4,
    "shorttermemployeebenefitsexpense": 1545000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 52000,
    "otherfinancecost": 207000,
    "increasedecreaseinnetdefinedbenefitliabilityasset": 1804000,
    "ifrssharebasedcompensationexpense": 982000,
    "weightedaverageshares": 2200000,
    "operatingexpense": 5888000000,
    "issueofconvertibleinstruments": 1282238000,
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 2200000,
    "financialassetsatfairvalue": 982000000,
    "addressofregisteredofficeofentity": "Transistorweg 5, 6534 AT Nijmegen, The Netherlands",
    "incorporationdate": "October 18, 2006",
    "countryofincorporationdate": "September 18, 2015",
    "numberofemployee": "11 at December 31, 2021, 9 at December 31, 2020 and 11 at December 31, 2019.",
    "auditfeeforstatutoryandconsolidatedfinancials": 182125000,
    "auditrelatedandotherservicesipointheusa": 200221000,
    "totalstatutoryauditorperformance": 382346000,
    "collegeofamericanpathologists": 13448,
    "accumulatedothercomprehensiveincome": 244300000,
    "netloss": 29000000,
    "netcashusedinoperatingactivities": 22500000,
    "cashequivalent": 58500000,
    "carriedforwardamount": 305022000,
    "netdeferredtaxassets": 76255500,
    "deferredtaxasset": 76256000,
    "redesignatedfinancialliabilityatfairvaluethroughprofitorloss": 630000,
    "officeequipment": 5000,
    "weightedvaluespercent": 1.5,
    "grossprofits": 22239000,
    "insurancerevenuerate": 0.91,
    "concludedagreementsdescription": "the Company had concluded agreements with 119 payors for ConfirmMDx (2020: 107; 2019: 90) and 54 payors for SelectMDx(2020: 42; 2019: 32). In 2018 Medicare established a Final Positive Local Coverage Determination for use of ConfirmMDx for ProstateCancer.",
    "segmentrevenuedescription": "the Company earned 98.6% (2020: 97.9%; 2019: 100%) of its revenue from external customers from its clinical laboratory testingservices and out-licensing of intellectual property. In 2021, the clinical laboratory testing in the U.S. CLIA laboratory represented97% of the Company’s revenue (2020: 95%; 2019: 95%), while the out-licensing of intellectual property revenue in Europerepresented 1.5% (2020: 3%; 2019: 5%).",
    "customergeneratingover": 0.38,
    "totalrevenue": 8509733,
    "noncurrentasset": 0.62,
    "salesandmarketingexpenses": 842000000,
    "generalandadministrativeexpensedescription": "A change in presentation for patent expenses has been brought in 2020to report patent expenses under Research and Development, previously under General and Administrative expenses.",
    "grantincome": 382000,
    "loanfacilitydescription": "Thefinancial results primarily relate to interest charges for the loan facility with Kreos Capital (as explained in detail in note14) for a total of $1,566,000 and for the interest charges on the lease liability for $229,000. ",
    "acquisitiontotalamount": 196000,
    "deferredtaxassetwhenutilisationisdependentonfuturetaxableprofitsinexcessofprofitsfromreversaloftaxabletemporarydifferencesandentityhassufferedlossinjurisdictiontowhichdeferredtaxassetrelates": 13400000,
    "incometaxrelatingtochangeinvalueofforwardelementsofforwardcontractsofothercomprehensiveincome": 84932000,
    "taxcreditcarryforwardexpirationperiod": 7,
    "incometaxrelatingtochangesinfairvalueoffinancialliabilityattributabletochangeincreditriskofliabilityofothercomprehensiveincome": 372000,
    "remainingamortisationperiodofintangibleassetsmaterialtoentity2019": 3.6,
    "remainingamortizationperiodofintangibleassetsmaterialtoentity1": 2.2,
    "projecteddiscountedperiod": "ten years",
    "descriptionofdiscountratesappliedtocashflowprojections": 0.1216,
    "descriptionofgrowthrateusedtoextrapolatecashflowprojections": 0.03,
    "recoverableamountofassetorcashgeneratingunit": 3400000,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": 5,
    "secondleaseagreementdescription": "In October of 2021, the company entered into a 35-month sublease agreement (the “SecondLease Agreement”) for 6,000 additional office space adjacent to the laboratory. Under the terms of the Alton Lease and SecondLease Agreement, rental payments escalate through the term of each agreement and the Company is subject to additional chargesfor common area maintenance and other costs. The new lease agreements from 2021 represent an additional right of use assets ofa total value of $1,518,000.",
    "costofinventoriesrecognisedasexpenseduringperiod": 3216000,
    "feeandcommissionexpense": 630000,
    "netdebt": 202500,
    "bankdebtinstrumentsheld": 9000000,
    "percentageofprincipalamountoftheinitialconvertibleloan": 0.25,
    "loanprocessingfees": 67500,
    "firstdiscretionaryconvertibleloan": 180000,
    "seconddiscretionaryconvertibleloan": 202500,
    "grossloancommitments": 45000000,
    "borrowingsinterestrate": 0.01,
    "dividendspaidordinarysharespershare": 0.85,
    "initialconvertibleloanpercentage": 1.5,
    "convertibleloanrepayablepercentage": 1.5,
    "creditderivativefairvalue": 810000,
    "descriptionofeffectofregulatoryframeworkonplan": "Thetotal change in fair value in 2021 amounts to ($80,000) and is composed as follows: ",
    "propertyplantandequipmentcarryingamountatcostofrevaluedassets": 5000,
    "discountratepercentage": 0.1216,
    "issuesfairvaluemeasurementassets": 176000,
    "derivativefinancialliabilities": 630000,
    "numberofcustomers": 1000,
    "creditriskcashequivalents": 58498000,
    "borrowingsadjustmenttointerestratebasis": 0.1956,
    "composedcashonhand": 7195000,
    "exchangerate": 0.1,
    "netamount": 7037000,
    "increasedecreasetoprofitlosstoreflectdilutiveeffectresultingfromassumedconversionofpotentialordinaryshares": 816000,
    "potentialloss": 668000,
    "loanagreements": 2,
    "numberofleases": 11,
    "potentialadditionalcash": 945000,
    "totalcost": 594000,
    "debtsinstrumentterm": "ten years",
    "cumulativetranchespercentage": 0.25,
    "warrantsgranted": 30000,
    "vestininstalmentpercentage": 0.25,
    "firsttranchepercentage": 0.25,
    "warrantoutstandingdescription": "Theweighted average exercise price of all outstanding warrants (vested and non-vested warrants; assuming 1 warrant = 1 share) is€1.53 or $ conversion 1.73 at December 31, 2021 (€1,74 or $ conversion 2.14 at December 31, 2020; €2.35 or $ conversion2.64 at December 31, 2019). The weighted average remaining contractual life of all outstanding warrants at the end of 2021 is7.18 years (2020: 6.70 years; 2019: 6.74 years). ",
    "expectedvolatilityterm": "two years",
    "directorsremunerationexpense": 863000000,
    "expectedreimbursementotherprovisions": 12000000,
    "reimbursementforexpenses": 302000000,
    "nonexecutivedirectorss1": 20000,
    "entityregistrantname": "MDXHEALTHSA",
    "tradingsymbol": "MDXH",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 155969226,
    "amendmentflag": "false",
    "entitycentralindexkey": 1872529,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-40996",
    "entityincorporationstatecountrycode": "Belgium",
    "entityaddressaddressline1": "15279Alton Parkway",
    "entityaddresspostalzipcode": 92618,
    "entityaddresscityortown": "Irvine",
    "entityaddresscountry": "CA",
    "contactpersonnelname": "MichaelMcGarrity",
    "entityaddressaddressline2": "Suite 100",
    "security12btitle": "Ordinary shares, no par value",
    "securityexchangename": "Nasdaq",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorname": "BDO Réviseurs d’Entreprises",
    "auditorlocation": "Zaventem, Belgium",
    "auditorfirmid": 1432,
    "cityareacode": "+1 949",
    "localphonenumber": "812-6979"
  }
]